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Abstract 
 
Objectives: Histone Deacetylase 1 (HDAC 1) is highly expressed in synovial tissues from 
rheumatoid arthritis (RA) patients. Hence, the aim was to determine if a novel HDAC inhibitor 
(HDACi) designed to target HDAC 1, NW-21, could inhibit the release of inflammatory 
cytokines and chemokines by TNF-α stimulate monocytes and osteoclastogenesis in vitro. 
Effects on inflammation and bone loss were subsequently assessed in collagen-antibody induced 
arthritis (CAIA) in mice.  
 
Methods: Human peripheral blood mononuclear cells (PBMCs) stimulated with receptor 
activator of nuclear factor kappa B ligand (RANKL) and macrophage colony stimulating factor 
(M-CSF) were used to determine effects of NW-21 on both osteoclast formation and activity. 
Anti-inflammatory activity of NW-21 was assessed using human monocytes stimulated with 
either tumor necrosis factor α (TNF-α) or lipopolysaccharide (LPS) for 24 hours and treated +/- 
NW-21. Real time PCR was used to determine mRNA expression of  monocyte chemotactic 
protein 1 (MCP-1), TNF-α, Macrophage Inflammatory protein 1 α (MIP-1α), IL-1 and RANTES. 
Effects of NW-21 in vivo was assessed using the CAIA model in mice with daily oral 
administrationat 5mg/kg/day. NW-21 was compared to Class I HDACi, MS-275, and a broad 
acting HDACi, 1179.4b. Effects on inflammation and bone were assessed using paw 
inflammation scoring, histology and live animal micro CT of the radiocarpal joints.  
 
Results: In vitro, HDACi NW-21 suppressed human osteoclast formation and activity as well as 
significantly reducing mRNA expression of chemokines, monocyte chemotactic protein (MCP)-1 
and macrophage inflammatory protein 1α (MIP-1α) in PBMCs stimulated by LPS or TNF-α. 
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Only the inhibitors that targeted HDAC 1, NW-21 and MS-275, reduced inflammation and bone 
loss in vivo, whereas the broad acting HDACi was not effective. 
 
Conclusion: The results indicate that inhibitors targeting HDAC 1, such as NW-21 and MS-275, 
may be useful for treating RA as they reduced both inflammation and bone loss.  
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Introduction 
 
Soft tissue inflammation, focal bone erosions and systemic bone loss are all characteristic 
features of rheumatoid arthritis (RA), that currently affects approximately 1% of the world’s 
population [1]. RA commonly affects the synovial joints, particularly the knees and fingers, 
resulting in joint inflammation and synovial hyperplasia associated with destruction of bone and 
cartilage.  The bone resorbing osteoclasts are responsible for the localized bone erosions with 
this being demonstrated in both human RA tissues [2-5] and animal models [6, 7]. Large 
multinucleated osteoclastic cells resorbing the subchondral bone have been detected at sites of 
bone loss in the joints [8, 9]. 
 
A variety of treatments exist for RA, ranging from the basic non-steroidal anti-inflammatory 
drugs (NSAIDs) to the more recently developed biologic anti-rheumatic drugs (DMARDs), such 
as the anti-TNF agents infliximab and adalimumab. Although these treatments suppress 
inflammation, their actions on the focal bone erosions are variable [10]. Many of these current 
treatments can also have adverse side effects when taken for a long time period and it can also 
take a considerable time for clinicians to identify the appropriate treatment(s) for individual 
patients [11-17]. During this delay in finding an effective treatment regime there can be 
continuing erosion of the bone that strongly impacts on normal joint function both in the short 
and longer term. More recently a disconnect between disease activity and structural damage has 
also been highlighted, hence treatments that could be administered immediately that directly 
target the early bone erosions would be beneficial [18]. Histone deacetylase (HDAC) inhibitors 
might have the potential to halt damage as well as suppress in the inflammation. 
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HDAC enzymes are thought to play an important role in regulating gene transcription by altering 
the acetylation status of histone proteins resulting in regulation of gene repression. These 
enzymes can also deacetylate many other non-histone signal transduction proteins that are 
important in multiple inflammatory events [16, 17]. HDAC enzymes with a catalytic zinc ion are 
classified into two main classes. Class I includes HDACs 1, 2, 3 and 8 and are primarily found in 
the nucleus [19]. Class II includes HDACs 4, 5, 7 and 9, which belong to Class IIa, and HDACs 
6 and 10, which belong to Class IIb. Class II enzymes are able to shuttle between the nucleus and 
cytoplasm. The inhibition of HDAC enzymes is considered to be a favourable strategy for the 
treatment of a wide variety of diseases, including malignancies and inflammatory diseases. 
Reductions in cancer cell growth have been shown by inhibiting differentiation of cells both in 
vitro and in vivo [20-24]. A range of HDACi are in different stages of clinical trials for treating 
both solid and hematological malignancies [25] with broad acting HDACi (Vorinostat (SAHA) 
and Romidepsin approved for clinical use to treat cutaneous T cell lymphoma. The effects of 
HDAC inhibitor (HDACi) treatment on inflammatory diseases appears to be related to its 
suppression of inflammatory cytokines, such as TNF-α and IL-1β [26]. Interestingly, the anti-
inflammatory effects are observed at much lower doses (10-100x lower) than those used to treat 
malignancies, making them attractive therapeutic options for the treatment of inflammatory 
diseases [27].  
 
A number of studies have demonstrated that various HDACi suppress disease activity in animal 
models of inflammatory arthritis [28-31]. In an adjuvant arthritis model, cyclic depsipeptide 
HDACi, FR901228 (FK228) had both prophylactic and therapeutic effects [29]. Phenylbutyrate 
and trichostatin A (TSA), both broad acting HDACi, have been shown to suppress joint swelling, 
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reduce subintimal mononuclear cell infiltration, inhibit synovial hyperplasia, suppress pannus 
formation, cartilage damage and bone destruction also in an adjuvant arthritis model [32]. More 
specific acting inhibitors, such as MS-275 which is HDAC1 selective, have also been reported to 
have significant anti-arthritic effects [28]. At relatively low doses (3 mg/kg/day), MS-275 
inhibited inflammation and bone loss while also reducing IL-1β and IL-6 serum levels [28], 
however this compound is also quite toxic. MS-275 has been reported to suppress HDAC 1 at 
concentrations below 0.1 µM [33] and is more preferential for HDAC 1 (IC50 0.3 µM) compared 
to HDAC 3 (IC50 8 µM) [34]. By comparison, a broad acting HDACi, such as suberoxylanilide 
hydroxamic acid (SAHA), requires higher doses (10 mg/kg/day) to reduce inflammation and 
bone damage. SAHA was shown to suppress both inflammation and bone erosion, but could not 
prevent the onset of arthritis [28]. These studies demonstrate the potential of more selective 
HDACi for treating arthritis. Broad acting inhibitors target a range of HDAC enzymes in both 
classes and in many cases it is unclear exactly which HDACs are targeted and to what extent 
they are inhibited. The broad inhibitory action increases the possibility of side effects during 
long-term administration due to the widespread expression of these enzymes in a variety of 
tissues and organs. Research is now progressing towards using more selective compounds that 
target specific HDACs or HDAC classes involved in disease processes. 
 
To date, only one HDACi, givinostat, has progressed to humans for the treatment of juvenile 
arthritis. In that study, 17 children with juvenile idiopathic arthritis (JIA) were treated with 
givinostat for up to 12 weeks [35]. No systemic toxicities or organ dysfunctions were observed 
and only mild to moderate side effects were reported. Patients treated with givinostat reported 
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improvements in mobility and wellbeing and there were also reductions in number of joints with 
active arthritis [35]. 
 
Recent studies have demonstrated elevated nuclear activity of HDACs in RA synovial tissue 
compared to osteoarthritis (OA) tissues [36] and HDAC 1 is highly expressed in synovial 
fibroblasts from RA patients [37]. High levels of HDAC 1 observed in RA tissues were found to 
correlate with TNF-α expression [37, 38], suggesting a link between HDAC activity and 
synovial inflammation. The high expression of HDAC 1 in RA along with the positive effects 
observed for MS-275 in animal models of arthritis suggests that targeting HDAC 1, possibly 
along with other class I HDACs could reduce disease activity. In this study, it was hypothesised 
that inhibitors targeting class I HDACs, would suppress inflammation and bone loss in vitro and 
in an animal model of inflammatory arthritis. Therefore, this study aimed to determine the effects 
of a novel HDACi (NW-21) on osteoclast formation and activity in vitro, cytokine and 
chemokine expression by human monocytes stimulated with TNF-α or E. coli LPS in vitro and 
on a collagen antibody induced arthritis (CAIA) in mice. HDACi NW-21 designed to target class 
I HDACs (1-3) was compared with an HAC 1-selective inhibitor, MS-275, and a novel broad-
acting HDACi, 1179.4b, previously shown to suppress bone loss in vitro and in a mouse model 
of periodontitis [39]. Based upon enzyme data {REF to Gupta et al, Curr Topic Med Chem) it 
would appear that NW-21 targets HDAC 1, 2, 3 better than MS-275 which only targets HDAC 1. 
More than 1µM concentrations of MS-275 are required to inhibit HDAC 2 and 3.  
 
In addition, expression of important factors involved in osteoclast formation and inflammation in 
vitro assays was assessed to gain further insights into mechanisms by which NW-21 inhibits 
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osteoclast resorption and inflammation. The results of this study indicate the importance of Class 
I HDACs for both anti-inflammatory and anti-resorptive activity. 
 
Methods 
 
Histone Deacetylase Inhibitors (HDACi) 
 
HDACi NW-21 (Figure 1) is a novel compound initially developed by researchers at the 
University of Queensland to inhibit cancer (compound 51 in [40]) and malaria (compound ASU-
13 in [41]). It was designed to specifically target Class I over Class II HDACs (e.g. inhibition of 
HDAC activity: IC50 = 0.021±0.02 µM for HDAC 1 (Class I), 0.042±0.02 µM for HDAC 2 
(Class I), 0.3 µM for HDAC 3 (Class I), >10 µM for HDAC 4 (Class IIa) 0.88±0.06 for HDAC 6 
(Class IIb), >1 µM for HDAC 7 (Class IIa), >3 µM for HDAC 8 (Class 1) ([42] and unpublished 
data). NW-21, MS-275 and 1179.4b (also obtained from the University of Queensland) with 
concentrations used being based on previous studies in vitro [43] and in vivo [39] and upon 
recommendation by the developers. MS-275 is also a Class I selective inhibitor (IC50 = 0.181 
µM for HDAC 1, 1.16 µM for HDAC 2, 2.31 µM for HDAC 3, >10 µM for HDAC 4, >10 µM 
for HDAC 6, >10 µM for HDAC 7 and >10 µM for HDAC 8 [42].  
 
In vitro Osteoclast Assay 
 
Peripheral Blood Mononuclear cells (PBMCs) were obtained by differential centrifugation from 
whole blood buffy coats obtained from the Australian Red Cross Blood Service (n=9) as 
previously described [43]. Ethical approval was obtained from the University of Adelaide 
Human Ethics Committee. Briefly, cells were seeded at 2x106 cells per mL on day 0 in α-
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minimal essential medium (a-MEM; Invitrogen, Melbourne, Victoria, Australia) supplemented 
with 10% fetal calf serum (FCS; Invitrogen, Life Technologies, Carlsbad, CA), 1% penicillin–
streptomycin (Invitrogen), and 1% L-glutamine (Invitrogen) with 100 nM 1a, 25(OH2)D3 
(vitamin D3) (Novachem, Melbourne, Victoria, Australia), 100 nM dexamethasone (Fauldings, 
Adelaide, South Australia, Australia), and 25 ng/mL of recombinant human M-CSF (Chemicon 
International Inc, Millipore, MA). Cells were maintained at 37˚C with 5% CO2 for a total of 17 
days. From day 7 onwards, human recombinant receptor activator of nuclear factor kappa B 
(RANKL) (50 ng/mL; Chemicon International Inc.) was added to the culture medium. Cells were 
treated with 5 fold dilutions of the HDACi NW-21 starting at 20 nM commencing on either day 
7 (coinciding with RANKL addition), day 10 or day 13, similarly to previous studies [43]. Serial 
dilutions of NW-21 were achieved in DMSO with a final concentration of 0.01% and hence 
controls were treated with 0.01% DMSO. Media was replaced every two days with the addition 
of RANKL and NW-21 (from day 7,10 or 13). 
Cell Viability 
 
The effect of NW-21 on cell viability was assessed over a concentration range of 0.16 nM-20 nM 
using a WST-1 assay (Roche Applied Science, Castle Hill, NSW, Australia). On day 14, 10 µL 
of cell proliferation reagent WST-1 was added to each well (100 mL media) followed by 
incubation for 2 h at 37˚C. A control blank consisted of culture medium with WST-1 reagent 
without any cells. Absorbance was measured at 450 nm following a 2 h incubation period. 
Absorbance in NW-21 treated wells was compared with that of controls. 
 
Osteoclast Formation 
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Cells were grown in the presence of NW-21 (0.16 nM– 20 nM) commencing from either day 7, 
10 or 13 in 16 well chamber slides (LabTek, Nunc International, Rochester, NY, USA). On day 
14, cells were fixed with 4% glutaraldehyde in Hank’s balanced salt solution (HBSS) and stained 
with a TRAP kit (Sigma, St. Louis, MO) according to the manufacturer’s instructions and as 
previously described [43]. Cells were counterstained using 0.5% w/v Methyl Green. TRAP 
staining was imaged using a light microscope (Nikon Microphot FXA Photomicroscope, Nikon 
Instruments Inc., Melville, NY, USA). Three representative areas were imaged for each 
concentration. The number of TRAP-positive multi-nucleated (more than 3 nuclei) cells for each 
concentration of NW-21 was compared with the controls (0.01% DMSO) for individual donors 
[43].  
 
Osteoclast Activity 
 
Cells for osteoclast activity assessment were grown on 5 mm sterile whale dentine slices. On day 
17, cells were trypsonised and the dentine washed with milliQ water to remove cells before 
mounting onto SEM stubs for analysis. Dentine slices were coated using carbon gold and then 
imaged with the Philips XL-20 Scanning Electron Microscope (Adelaide Microscopy). Three 
representative images were taken for each dentine piece at 150x magnification and quantitated 
using Image J analysis software (National Institutes of Health, USA). The area of pit resorption 
for each concentration of NW-21 was expressed as a percentage of the total area of the dentine 
[43]. Resorption in treated wells was represented as a percentage of the average area of 
resorption in the control well (0.01% DMSO). 
 
Inflammatory Gene Expression In Vitro 
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PBMCs were obtained from buffy coats and seeded at 2x106 cells per mL in 48 well trays on day 
0 in α-MEM with the supplements as described above. Cells were incubated at 37˚C with 5% 
CO2 for 2h [44]. Following this, cells were treated with either human recombinant E. coli 
lipopolysaccharide (LPS) (100 ng/ml) (Chondrex Inc., Arthrogen-CIAs Arthritogenic 
Monoclonal Antibodies, Redwood WA, USA) or tumor necrosis factor α (TNF-α) (10 ng/ml) 
(Recombinant Human TNF-alpha, RnD Systems, Minneapolis, MN USA) with and without NW-
21 (20 nM). Controls were treated with 0.01% DMSO. Cells were maintained at 37˚C with 5% 
CO2 for a further 24h before RNA collection as described below.  
 
Real Time PCR to Determine mRNA Expression 
 
RNA was extracted from cells grown in the presence of HDACi NW-21 and control wells at 
different time points throughout the osteoclast culture (days 0,7,10, 14 and 17) using Trizol 
(Invitrogen Life Technologies, Carlsbad, CA). For the inflammation assay, RNA was collected 
after 24 hours of incubation with either TNF-α or LPS with or without HDACi NW-21. Reverse 
transcription was conducted using a Corbett real time PCR machine (Corbett Research Rotor 
Gene RG-3000; Corbett Life Science, Mortlake, NSW, Australia). The RT reaction included 250 
ng of random hexamer (Geneworks, Adelaide, SA, Australia) and 200 U of Superscript III 
Reverse Transcriptase according to the manufacturer’s instructions to produce cDNA. Real Time 
PCR was carried out using Platinum SYBR Green qPCR Supermix-UDG (Invitrogen Life 
Technologies, Carlsbad, CA) according to the manufacturer’s instructions. The mRNA 
expression of osteoclast related genes nuclear factor of activated T cells (NFATc1), TNF 
receptor factor-6 (TRAF-6) and osteoclast associated receptor (OSCAR) were compared between 
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treated and control cells. Primers were those previously used: NFATc1 [43], TRAF-6 [43] and 
OSCAR [45]. For the in vitro inflammatory assay cytokines included TNF-α, IL-1β and 
chemokines MCP-1, MIP-1α, IL-6 (designed using Primer3Plus), RANTES [46] Reaction 
mixtures consisted of 1µg cDNA, 2x supermix (containing SYBR Green 1 dye), 300 nM of 
forward and reverse primer and this was made up to a total volume of 15µL with diethyl 
pyrocarbonate (DEPC) water. PCR was performed in triplicate for each sample. mRNA 
expression was determined relative to endogenous reference gene human acidic ribosomal 
protein (hARP; [47]). The relative quantification of the mRNA expression for each of the genes 
was then calculated using the comparative Ct method 2-ΔΔCt [48]. 
 
Collagen Antibody Induced Ar thr itis (CAIA) Model 
 
Female Balb/c mice (29 animals) at 6-8 weeks of age were used for this study. Mice had access 
to food and water ad labium. Animal ethics approval was obtained through the University of 
Adelaide Animal Ethics Committee. The experiment consisted of 5 groups; group 1: controls no 
disease (n=6), group 2: CAIA with vehicle treatment (n = 6), group 3: CAIA with HDACi 
1179.4b treatment at 5 mg/kg/day (n = 5), group 4: CAIA with HDACi treatment NW-21 at 5 
mg/kg/day (n = 6) and group 5: CAIA with HDACi MS-275 treatment at 10 mg/kg/day (n = 6).  
 
Treatments 
HDACi NW-21, MS-275 and 1179.4b were all administered in olive oil due to their lipophilic 
nature. Treatments were administered daily via oral gavage [39] commencing on day 4 following 
the LPS injections. Groups 1 and 2 mice were treated with the olive oil vehicle.  
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CAIA Induction 
 
CAIA was induced by injecting mice intravenously via the tail vein with 150 µL (1.5 mg) of a 
monoclonal antibody against type II collagen (day 0) (Chondrex Inc., Arthrogen-CIAs 
Arthritogenic Monoclonal Antibodies, Redwood WA, USA) as previously described [49]. 
Control mice were injected with PBS only. Two days later mice were given an intraperitoneal 
(i.p.) injection of 20 µL (10 µg) of LPS (Chondrex Inc). Control animals were injected with only 
PBS. Mice were monitored daily by two experienced observers for a total of 14 days. Clinical 
record sheets were maintained throughout the study detailing changes in body weight, 
dull/ruffled coat, temperament, reduced food/water intake or a reluctance to move). Paws were 
assessed for signs of redness and swelling daily by two experienced observers. To assess 
inflammation each paw was given a score from 0 to 4 giving a total maximum score of 16 for 
each animal [49]. 0=normal paw, 1=mild but definite redness and swelling of the wrist/ankle, 
2=moderates welling and redness of the wrist/ankle with digit involvement, 3=severe swelling of 
the wrist/ankle with multiple digit involvement and 4=maximum inflammation within the entire 
paw, wrist/ankle with many digits involved. 
 
Live Animal Micro CT Scanning 
 
A live animal micro CT scan was initially conducted to obtain baseline measurements (4 days 
prior to CAIA induction) followed by a final CT scan at the completion of the study (day 14). 
Scans were conducted using an in vivo animal micro-CT scanner (Bruker formally known as 
SkyScan, SkyScan1076, Kontich, Belgium) situated in Adelaide Microscopy. The specifications 
used for scanning and machine details have been published previously [49]. Scanning was 
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conducted at 74 kV/136 mA with a pixel size of 18 mM, 1 mm aluminium filter and frame 
averaging of 1. Mice were initially anaesthetized with an i.p. injection (rat/mouse anaesthetic – 1 
mL xylazine, 2 mL ketamine (100 mg/mL), 17 mL of water in the injection, 0.3 mL for a 30 g 
mouse). Mice were aligned using polystyrene holders with the front paws being included in the 
scanning region of interest. Scans were reconstructed using SkyScanN’ Recon program and then 
realigned to allow for the same area to be analysed using SkyScan program Data Viewer. Bone 
volume analysis of the radiocarpal joints were conducted using SkyScan’s CTAn program 
(SkyScan Bruker, Kontich, Belgium). The same reference point with the radiocarpal joints was 
utilised for all analysis with 100 slices either side of this reference point being included in the 
region of interest to be analysed as previously described [49].  
 
Histological Analysis 
 
At the conclusion of the experiment, front paws were collected and fixed in 10% NBF for 48 h 
before decalcification in 10% EDTA for 8 weeks. Specimens were then processed and paraffin 
embedded. Sagittal sections (7 µm) of the radiocarpal joints were prepared. Routine H&E 
staining was conducted. Semiquantitative analysis was carried out by two blinded observers 
using a 4-point scale as previously described [49]. Scoring was based on the numbers of 
inflammatory cells with the radiocarpal joints (lymphocytes, plasma cells neutrophils or 
macrophages). Normal tissue (<5% inflammatory cells) was scored a 0, mild inflammation (5–
20% inflammatory cells) was scored a 1, moderate inflammation (20–50% inflammatory cells) 
was scored a 2 and severe inflammation with a massive immune cell infiltration (>50% 
inflammatory cells) was scored a 3. Bone and cartilage destruction was assessed by: 0=normal, 1 
=mild cartilage destruction, 2=evidence of both cartilage and bone destruction, 3= severe 
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cartilage and bone destruction. Pannus formation: 0=no pannus, 1=pannus formation [49]. 
Tartrate resistant acid phosphatase (TRAP) staining of the radiocarpal joints was conducted to 
detect osteoclasts on the bone surface and in the soft tissues. TRAP staining methods were 
adapted from [50]. Slides were stained in TRAP for 20 minutes at 37◦C before rinsing and 
counterstaining with haematoxylin. TRAP staining was imaged and the number of TRAP 
positive multinucleated cells was quantitated in the radiocarpal joint in an area of 1.92mm2. 
 
Statistical analysis 
Statistical analysis was conducted using GraphPad Prism 6 (GraphPad Software Inc.)  For TRAP 
stain quantitation and pit resorption analysis a one-way analysis of variance, followed by a 
Bonferoni’s Post Hoc Test was conducted. Students T-Test was used to compare between treated 
and controls for the PCR results at each time point relative to expression at day 7. In the arthritis 
model a one way analysis of variance was used to compare between different groups for paw 
scoring, CT analysis and histological scoring. 
 
Results 
Osteoclast Formation and Activity 
 
Cells treated for 24 h with HDACi NW-21 showed no significant changes in viability at all 
concentrations tested (0.16– 20.0 nM) (data not shown). RANKL stimulation resulted in the 
formation of TRAP positive multinucleated cells detected at day 14 (Figure 2A and these cells 
resorbed pits in the mineralised substrate by day 17 (Figure 2B). Treatment of the cells with 
HDACi NW-21, commencing from day 7 coinciding with RANKL addition, resulted in a 
significant reduction in the number of multinucleated TRAP positive cells for the highest 
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concentrations (20 nM (p<0.001) and 4 nM (p<0.01)) (Figure 3A). This reduction was associated 
with a similar reduction in resorption activity (Figure 2B). At all concentrations above 0.16 nM 
there was a significant reduction in the area of pit resorption (p<0.01) (Figure 3). There was a 
marked reduction with increasing concentrations, 1.1% of the control area resorbed with 20 nM 
treatment and 21% with 4 nM NW-21 treatment. Experiments were carried out with treatments 
commencing on day 10 and day 13 to assess effects on the later stages of osteoclast 
differentiation. Interestingly, treatment from either day 10 or day 13 did not significantly reduce 
either the formation of TRAP multinucleated cells or resorption (Figure 3A and B). 
 
Gene Expression in Osteoclasts 
 
Effects of NW-21 treatment commencing from day 7 on osteoclast related genes were assessed 
using real time PCR (Figure 3C). NW-21 treatment resulted in a 1.4 fold reduction in the mRNA 
expression of TRAF-6 (p<0.001) at day 10. NFATc1 mRNA expression was also significantly 
decreased at day 10 (p<0.05) and at day 17 however at this time point it was not significant 
(p>0.05). OSCAR mRNA expression was significantly reduced by 1.3 fold at day 10. At day 10, 
there was a 2.3 fold increase in MCP-1 mRNA expression relative to day 7, and this expression 
was reduced throughout osteoclast differentiation. At day 10, HDACi NW-21 resulted in a 1.7 
fold reduction in the MCP-1 mRNA expression (p<0.05).  
 
Inflammatory Cytokines and Chemokine Gene Expression 
 
Monocytes stimulated with either LPS or TNF-α were treated with NW-21 (20 nM). This 
treatment resulted in a significant (p<0.05) reduction in mRNA expression of inflammatory 
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chemokines MIP-1α and MCP-1. For TNF-α treated cells, there was a 1.7 fold reduction in the 
relative mRNA expression and in LPS stimulated cells there was a 4.6 fold reduction. In both 
cases there was no significant change in the mRNA expression of cytokines TNF-α, IL-1β or 
RANTES as shown in Figure 5 (p>0.05). There was a 2.2 fold reduction in the relative mRNA 
expression of RANTES in both TNF- stimulated and 1.7 fold reduction in LPS stimulated 
monocytes although this was not significant. NW-21 treatment caused a 4.1 fold decrease in IL-
1β mRNA expression in LPS stimulated cells and a 2.7 fold decrease in IL-1β mRNA in TNF-α 
stimulated cells (p>0.05).  In TNF-α stimulated cells there was a 2.3 fold reduction in IL-6 
mRNA expression, whilst unexpectedly in NW-21 treated LPS stimulated cells there was an 
increase in IL-6 expression although not shown to be significant (p>0.05). 
 
Collagen Induced Ar thr itis 
 
The effects of NW-21 (5 mg/kg/day) daily oral treatment commencing following LPS 
administration on day 4 were assessed in a CAIA mouse model. The effects of NW-21 were 
compared to broad acting inhibitor 1179.4b and Class I selective inhibitor MS-275.  
 
Weight Changes 
 
Mice were monitored daily for changes in weight and all the disease groups did lose weight (9%) 
at day 3 and this is likely associated with the LPS injection (data not shown). Although there was 
no statistically significant difference, there was less weight loss by all HDACi treatment groups. 
 
Inflammation 
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Induction of inflammatory arthritis resulted in significant swelling and redness in the paws as 
shown in Figure 4A. Paw inflammation was first noted from day 4 following the LPS injections, 
which peaked at day 10 and began to reduce over the following 4 days (Figure 4I). There was no 
significant effect of 1179.4b treatment on the paw scoring at any of the time points (p>0.05). 
Both NW-21 and MS-275 treated groups had significantly reduced paw scores compared to 
untreated mice, as depicted in the macroscopic images in Figure 4B and D. The histology (Figure 
5A) of the tissues was consistent with paw inflammation seen macroscopically with evidence of 
extensive inflammatory cell infiltration in both the vehicle treated (oil) (and 1179.4b treated 
mice. There was very little inflammatory cell infiltration in the paws of mice treated with either 
NW-21 or MS-275 (Figure 5B). There was also evidence of pannus formation in the mice given 
the vehicle or 1179.4b that was mostly absent in the NW-21 and MS-275 treated groups (Figure 
5C). In the NW-21 treated group, 1 of the 6 mice failed to respond to NW-21 treatment in any 
way and this caused a lack of statistical significance other than in paw scoring on days 10 and 
11.  
 
Bone Loss 
 
Analysis using live animal CT also revealed evidence of bone loss throughout the 14 days in the 
diseased mice (Figure 4J). There was an expected normal growth of the mice with a 8.9% 
increase in bone volume in the controls over the experimental period. In diseased (oil) mice there 
was on average a 1% decrease in bone volume. In 1179.4b treated mice there was greater bone 
loss than the oil treated mice with an average 4.4% reduction in bone volume overtime although 
not significant. There was an average 8.7% increase in bone volume in NW-21 treated mice and 
a 12% increase in MS-275 treated mice as shown in Figure 4J. This did not however reach 
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statistical significance when compared to untreated mice. There was a marked reduction in bone 
and cartilage destruction following NW-21 and MS-275 treatments as assessed on H&E stained 
radiocarpal joints. In both the diseased group and the 1179.4b treated mice there was evidence of 
large numbers of TRAP positive cells on the bone surfaces and in the inflamed soft tissues as 
depicted in Figure 6. Very few TRAP positive cells were found in the joints from mice treated 
with either NW-21 or MS-275 (Figure 5A and E). 
 
Discussion 
 
The in vitro results of this study support the hypothesis that inhibitors targeting HDAC 1 would 
suppress both inflammation and bone loss. Novel HDACi NW-21 reduced the formation of 
TRAP positive osteoclasts as well as the osteoclasts resorptive activity in a concentration-
dependent manner. Some previous studies have demonstrated that HDACi can suppress 
osteoclast differentiation and activity in vitro, but these studies used broader acting inhibitors of 
HDACs, such as, trichostatin A (TSA) [51, 52], suberanilohydroxamic acid (SAHA) [43], 
ITF2357[29] and 1179.4b [43]. We have previously shown that MS-275, which inhibits HDAC 1 
and to a much lesser extent other Class I HDACs [42] was able to suppress human osteoclast 
formation and activity [43]. However, MS-275 was only effective at relatively high 
concentrations (100 nM) and hence this could suggest that other class I HDACs may be 
important such as HDAC 2. The suppression of osteoclasts with NW-21 was surprising given 
that HDAC 1 expression was not shown to be significantly increased during osteoclast 
development, while HDACs 5 and 8 were highly expressed as osteoclasts formed [43]. These 
results could be related to the potency of NW-21 or could suggest that although HDAC 1 
expression is not markedly increased during osteoclastogenesis, its activity is required for 
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osteoclast differentiation. It is clear that HDAC 2 may also be important which is not surprising 
given that HDAC 1 and 2 function together in a protein complex and are thought to be redundant 
[53]. NW-21 was more effective at suppressing osteoclasts at lower concentrations than MS-275, 
possibly supporting a role for both HDAC 1 and 2. Studies by others have also focused on the 
roles of HDAC 3 and HDAC 7, with suppression of HDAC 7 accelerating osteoclast 
differentiation and suppressing HDAC 3 shown to inhibit differentiation [54]. While NW-21 
inhibits HDAC1 (IC50=0.021 µM) and also HDAC 2 (IC50=0.042±0.02 μ M) at low 
concentrations it can also weakly inhibit HDAC 3 (IC50 = 0.3µM), so further studies may be 
needed to determine if NW-21 inhibits osteoclastogenesis by inhibition of HDAC 1 and 2 in 
vivo. Over-expression of HDAC 5 has been shown to reduce RANKL-mediated acetylation of 
NFATc1 (NFATc1), indicating HDACs can regulate NFATc1 activity [55]. While these studies 
show the importance of HDACs in osteoclast differentiation, it is still unclear which HDACs are 
the most important. It may well be that it is a combination of HDACs that influence these 
processes, some being more important than others. 
 
An interesting observation, when commencing with NW21 treatment later than day 10, was that 
this did not result in a decrease in osteoclast activity. This is similar to the effect of HDACi 
1179.4b, which suppressed both osteoclast formation and activity when treatment was 
commenced from day 7, but not at later times [43]. In order to better understand the mechanisms 
involved, mRNA analysis was conducted. NW-21 treatment from day 7 resulted in a reduction in 
the mRNA expression of TRAF-6 and NFATc1, similar to that for 1179.4b. The reduction in 
TRAF6 at day 10 may be responsible for the reduced NFATc1 expression seen later as TRAF-6 
signalling, initiated soon after RANK/RANKL interaction, is up stream of NFATc1 elevation 
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essential during the terminal stages of osteoclast formation [56]. This is consistent with the lack 
of effect of NW-21 after day 10 (3 days after RANKL administration).  
 
 
NW-21 caused a significant reduction in expression of chemokines MCP-1 (also referred to as 
Chemokine (C-C motif) ligand 2 (CCL2)) and MIP-1α (also referred to as Chemokine (C-C 
motif) ligand 3 (CCL3). MCP-1 is known to recruit monocytes, memory T cells, and dendritic 
cells to sites of inflammation. It is also reportedly produced by synovial cells and infiltrating 
monocytes in RA [57]. RA synovial tissue macrophages were found to constitutively express 
MCP-1 [57]. TNF-α and IL-1 stimulation of synovial cells resulted in increased MCP-1 mRNA 
expression[58]. The anti-TNF drug, etanercept, was shown to significantly reduce serum levels 
of MCP-1 in RA patients[59]. These levels correlated with disease activity, confirming a role for 
MCP-1 in the pathogenesis of RA inflammation [59]. MCP-1 was also reported to be expressed 
by mature osteoclasts and shown to promote human osteoclast formation in absence of RANKL, 
however, these cells were unable to resorb bone [60]. Macrophage inflammatory protein 1α 
(MIP-1 α) is known to be produced by macrophages following stimulation by bacterial 
endotoxins [61]. It is known to be chemotactic for PMNs, macrophages and T cells [61]. 
Significantly higher levels of MIP-1α have been shown in synovial fluids from patients with RA 
compared to OA. Mononuclear cells from synovial fluid produce MIP-1α along with synovial 
fibroblasts and this can be stimulated by TNF-α or LPS [62]. MIP-1α has also been shown to 
induce osteoclast formation [63]. Both MCP-1 and MIP-1α were significantly reduced by NW-
21 treatment in this study. A lack of MCP-1 in osteoclasts has been shown to result in a down-
regulation of NFATc1 and osteoclast suppression [64]. This is consistent with the notion that 
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inhibition of NFATc1 and osteoclast formation occurs downstream of MCP-1 suppression 
initiated by inhibition of HDAC 1. Studies by others have also shown that HDACi can suppress 
NFATc1 [29] in osteoclasts in vitro whilst others have shown that broad acting HDACi (TSA 
and sodium butyrate) can suppress TNF induced NF-Kappa B activation in RAW264 cells [51]. 
These results in this study have revealed a role for HDACs in MCP-1 expression and hence 
osteoclast differentiation. It is clear that HDACi may work via different mechanisms in 
osteoclasts and this could be dependent on what specific HDACs are targeted. Further studies are 
clearly needed to elucidate which specific HDACs are involved in the osteoclast signaling 
pathways. 
 
The second part of the study hypothesis, that HDACi (NW-21 and MS-275) which target HDAC 
1 would suppress inflammation and bone loss, was also supported by our findings in the CAIA 
mouse model.   Arthritis was induced in mice using the CAIA model which induced features 
including inflammation, cartilage and bone destruction.  There was some variation in levels of 
inflammation and bone destruction observed in untreated CAIA mice although this is a normal 
variation observed with this model. Both NW-21 and MS-275 suppressed inflammation as 
demonstrated by both reduced clinical paw scoring and histologically with scoring for 
inflammatory infiltrate reduced in treated mice. In this model, 1179.4b did not reduce 
inflammation in paws. Surprisingly, the effects of both 1179.4b and MS-275 were opposing in a 
model of periodontal disease, with 1179.4b suppressing bone loss despite having no effect on 
inflammation and MS-275 reducing inflammation but having no effect on bone loss [39]. Given 
the similarities between periodontitis and RA and the relationship between the two pathologies 
[49], it was expected that 1179.4b would also be able to suppress bone loss in RA. However, this 
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lack of effect is most likely due to differences in HDACs involved in the two diseases, the 
capacity of 1179.4b to also inhibit all other HDACs may lead to detrimental effects that 
overwhelm HDAC1-mediated pathology. Several studies point to the importance of HDAC 1 in 
RA with increased expression in disease [37] and its suppression inhibits inflammation and bone 
resorption. MS-275 selectively targets HDAC 1 (IC50=181 nM) over HDAC 2 (IC50=1155 nM) 
and HDAC 3 (IC50=2311nM) [42]. In regards to effects on bone loss both MS-275 and NW-21 
suppressed radiocarpal joint erosion. MS-275 although not significant was slightly more 
effective in suppressing both inflammation and bone resorption in the CAIA model. NW-21 
targets HDAC 1 and 2 and, given that MS-275 predominately targets HDAC 1, confirms the 
importance of HDAC 1. This importance of targeting HDAC 1 in RA is also consistent with a 
report showing that MS-275 has greater anti-arthritic activity than the broader acting HDACi 
SAHA [28]. In this CIA mouse model MS-275 was shown to reduce serum IL-6 and IL-1beta 
levels [28]. Recent studies have also shown that MS-275 was able to suppress cytokine-induced 
MMP1 and MMP13 in human articular chondrocytes [65]. A recent study demonstrated that a 
novel HDACi MPT0G009, which targets class I HDACs (1,2,3 and 8) as well as class II HDAC 
6, was able to suppress paw swelling and bone destruction in a rat adjuvant arthritis model.  
MPT0G009 was compared to SAHA in vitro and shown to reduce cytokine release by LPS 
stimulated macrophages with overexpression of HDAC 1 shown to reduce the effects of 
MPT0G009 [66]. These studies highlight the importance of targeting HDAC 1 although the 
effects of specific HDAC 1 inhibition in arthritis are not known and with the development of 
even more selective inhibitors this will become possible. Assessment of the effects of these 
inhibitors on acetylation levels both histone and non-histone proteins in vivo is warranted in the 
future. 
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The results of this study highlight the importance of HDAC 1 in the pathogenesis of RA. The 
HDACi, NW-21, targets both HDAC 1 and HDAC 2 (both class I HDACs) was able to suppress 
osteoclast resorption and inflammation in vitro and in vivo. This may be due to the ability of 
NW21 to suppress chemokines, MCP-1 and MIP-1α, as these chemokines are important in 
osteoclast formation as well as inflammation. In addition, the inhibitory effects of HDACi NW-
21 on osteoclasts occurs upstream of NFATc1 expression and are likely to be due to suppression 
of TRAF6 and/or chemokines that are elevated following RANKL/RANK interaction. Overall, 
the results demonstrate that a safely tolerated inhibitor of HDAC 1, such as NW-21, might be 
very useful for the treatment of RA as such a drug has the capacity to simultaneously target both 
inflammation and bone resorption. 
 
Key messages 
1. HDACi NW-21 designed to target HDAC 1 suppressed human osteoclast bone loss in 
vitro. 
2. NW-21 suppressed mRNA expression of MCP-1 and MIP-1α	 in TNF-α	 or LPS 
stimulated monocytes. 
3. NW-21 and MS-275 that both target HDAC 1 suppressed inflammation and bone loss in 
a collagen antibody induced murine arthritis. 
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Figure 1.  
Chemical structure of HDACi NW-21developed at the Institute for Molecular Bioscience at the 
University of Queensland. Chemical formula: C26H31N5O4. Molecular Weight: 477.56 
 
Figure 2.  
Representative TRAP stained sections (10x mag) (A,C, E, G, I)and scanning electron microscope 
images of dentine pieces (imaged using the XL-20 at 150x mag) (B, D. F, H, J). (A, B): Control 
(no HDACi treatment 0.01% DMSO). HDACi NW21 treatment commencing from day 7 at (C, 
D): 20 nM; (E, F): 4nM; (G, H): 0.8nM; and (I, J): 0.16nM.  
 
Figure 3.  
A) Average fold change in the number of TRAP positive multinucleated (>3 nuclei) cells relative 
to control (0.01% DMSO) Controls =1 (n=9). NW-21 treatment commencing from day 7 (n=9), 
day 10 (n=4) and  day 13 (n=4). 
B) Percentage area of pit resorption on dentine expressed as a percentage of the control area 
(0.01% DMSO). NW-21 treatment commencing from day 7 (n=9), day 10 (n=4),13 (n=4). 
Bars represent mean±SEM. ** p<0.01 and *** p<0.001 compared to control.  
C) Fold change in the relative mRNA expression assessed using real time PCR analysis. Relative 
to endogenous gene hARP. Fold change at days 10, 14 and 17 relative to day 7. n=3 healthy 
donors. Bars represent mean±SEM. * p<0.05 *** p<0.001 compared to control (0.01% DMSO).  
 
Figure 4.  
Representative macroscopic images of the front paws (A) CAIA +Oil B) CAIA+NW-21 C) 
CAIA+1179.4b D) CAIA+MS-275. 
Representative images of the front left-hand side paws. 3D models created from micro CT 
analysis conducted at day 14 (final day) using SkyScan program ANT. (E) CAIA +Oil F) 
CAIA+NW-21 G) CAIA+1179.4b H) CAIA+MS-275.  
I) Average daily (0-14) clinical paw scoring out of a total of 16. * p<0.05 NW-21 compared to 
oil. # p<0.05 MS-275 compared to oil.  To assess inflammation each paw was given a score from 
0 to 4 giving a total maximum score of 16 for each animal [49].  
J) Average percentage change in bone volume (BV) from scan 1 (4 days prior to mAb injection) 
to scan 3 (day 14) as assessed using micro CT with the SkyScan 1076.  
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Figure 5.  
A) H&E stained sections of the corresponding radiocarpal joint imaged at 20x and 4x 
magnification. TRAP stained images of the corresponding radiocarpal joints at 20x and 4x 
magnification. 
B) Average inflammation score of H&E stained sections out of a total of 3. Scoring was based on 
the numbers of inflammatory cells with the radiocarpal joints (lymphocytes, plasma cells 
neutrophils or macrophages).  
C) Presence of pannus on H&E stained sections. Scoring for pannus formation: 0=no pannus, 
1=pannus formation. 
D) Average Bone and Cartilage destruction score of H&E stained sections total score /3 Bone 
and cartilage destruction was assessed by: 0=normal, 1 =mild cartilage destruction, 2=evidence 
of both cartilage and bone destruction, 3= severe cartilage and bone destruction. 
E) Average number of TRAP+ multinucleated cells on bone surface in 1.92mm2 area of the 
radiocarpal joint.  
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